Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Danazol is a synthetic steroid approved in 1976 for the treatment of endometriosis-associated pain. Despite its established efficacy, its clinical use has markedly declined due to androgenic and metabolic adverse …
Endometriosis has limited treatment options, prompting the search for data-driven therapeutics. We previously used a transcriptomics-based computational drug repositioning pipeline and identified several drug candidates. Fenoprofen, our top in silico …
Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …
Background/Objectives: The NLRP3 inflammasome-Caspase-1-IL-1β pyroptotic axis participates in peripheral inflammatory responses, yet its function in peripheral-central neuroimmune crosstalk underlying endometriosis (EM)-associated pain remains unclear. This study aimed to clarify whether …
The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …
The most common symptom of endometriosis is pain. The pathogenesis of endometriosis-associated pain remains unclear. In this review, we illustrate the pathogenesis of endometriosis-associated pain and the mechanisms of dienogest …
Endometriosis is a chronic estrogen-dependent condition affecting women of reproductive age and commonly presents with dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. In a substantial proportion of patients, pain persists …
Endometriosis affects approximately 10% of reproductive-aged women worldwide and is a leading cause of chronic pelvic pain. Despite its high prevalence and substantial socioeconomic burden, the mechanisms underlying endometriosis-associated pain …
Estrogen stimulates corticotropin-releasing hormone (CRH) expression in endometrial tissue, and CRH signaling contributes to inflammation and pain, suggesting a mechanistic role in endometriosis pathophysiology. We previously identified elevated CRH receptor-1 …